tirzepatide cardiovascular outcomes study 💉 In a large real-world study, was associated with a lower incidence of major vs semaglutide: 📊 Composite CV outcome: 1.90% vs 2.18% (HR 0.86, p=0.01) ❤️ New-onset heart Tirzepatide cardiovascular event risk assessment:

In the post-menpausal years women gain on average about 1.5 pounds per yearsome even more

There were some early reports when GLP-1s first hit the market that they could cause depression in some people

This is one of the most searched questions about GLP-1 weight loss medications and the answer surprises many people

Staying hydrated and eating small, protein-rich meals can also help

3 Crucially, both Wegovy and Zepbound are intended to be used in combination with a reduced-calorie diet and increased physical activity to achieve their full benefits

Repeated injections in the same spot can cause lipodystrophy, the formation of hard or lumpy tissue that affects absorption